EA200971093A1 - Терапевтические композиции и их применение - Google Patents
Терапевтические композиции и их применениеInfo
- Publication number
- EA200971093A1 EA200971093A1 EA200971093A EA200971093A EA200971093A1 EA 200971093 A1 EA200971093 A1 EA 200971093A1 EA 200971093 A EA200971093 A EA 200971093A EA 200971093 A EA200971093 A EA 200971093A EA 200971093 A1 EA200971093 A1 EA 200971093A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- application
- therapeutic compositions
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- VAYISIYCRRTUOV-UHFFFAOYSA-N 1-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1=CC=C2N(OC)C=C(C(O)=O)C(=O)C2=C1 VAYISIYCRRTUOV-UHFFFAOYSA-N 0.000 abstract 1
- -1 3-chloro-2-fluorobenzyl Chemical group 0.000 abstract 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 abstract 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 abstract 1
- 102000018832 Cytochromes Human genes 0.000 abstract 1
- 108010052832 Cytochromes Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 abstract 1
- 229960003277 atazanavir Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94730607P | 2007-06-29 | 2007-06-29 | |
| US4092008P | 2008-03-31 | 2008-03-31 | |
| PCT/US2008/068339 WO2009006199A1 (en) | 2007-06-29 | 2008-06-26 | Therapeutic compositions and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200971093A1 true EA200971093A1 (ru) | 2010-08-30 |
Family
ID=39831893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200971093A EA200971093A1 (ru) | 2007-06-29 | 2008-06-26 | Терапевтические композиции и их применение |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20090093467A1 (enExample) |
| EP (1) | EP2167088A1 (enExample) |
| JP (3) | JP5547066B2 (enExample) |
| KR (1) | KR20100040892A (enExample) |
| CN (2) | CN101686972B (enExample) |
| AP (1) | AP2965A (enExample) |
| AR (1) | AR067183A1 (enExample) |
| AU (1) | AU2008270630B2 (enExample) |
| BR (1) | BRPI0813000A2 (enExample) |
| CA (1) | CA2692101A1 (enExample) |
| CO (1) | CO6251237A2 (enExample) |
| EA (1) | EA200971093A1 (enExample) |
| EC (1) | ECSP109897A (enExample) |
| IL (1) | IL202744A0 (enExample) |
| MX (1) | MX2009013829A (enExample) |
| NZ (1) | NZ582086A (enExample) |
| SG (1) | SG182229A1 (enExample) |
| TW (1) | TW200914011A (enExample) |
| WO (1) | WO2009006199A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101524165B1 (ko) * | 2005-12-30 | 2015-06-01 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법 |
| SI2049506T2 (sl) | 2006-07-07 | 2024-07-31 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtikov |
| HRP20090213B1 (hr) | 2006-09-12 | 2016-12-02 | Gilead Sciences, Inc. | Postupak i međuprodukti u pripravi inhibitora integraze |
| ES2779826T3 (es) * | 2007-02-23 | 2020-08-20 | Gilead Sciences Inc | Moduladores de propiedades farmacocinéticas de agentes terapéuticos |
| CN101686972B (zh) * | 2007-06-29 | 2013-08-14 | 吉里德科学公司 | 治疗用组合物和方法 |
| CN103356622A (zh) * | 2007-06-29 | 2013-10-23 | 吉里德科学公司 | 治疗用组合物及其用途 |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX342377B (es) | 2008-05-02 | 2016-09-27 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| CN102917695A (zh) * | 2010-04-09 | 2013-02-06 | 百时美施贵宝公司 | 具有改进的pH效应的阿扎那韦硫酸盐制剂 |
| US20130274254A1 (en) * | 2010-12-21 | 2013-10-17 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
| CA3131037A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
| AU2013296289B2 (en) | 2012-08-03 | 2017-10-05 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| SI3067358T1 (sl) | 2012-12-21 | 2019-12-31 | Gilead Sciences, Inc. | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
| AU2014286993B2 (en) | 2013-07-12 | 2018-10-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| US9463194B2 (en) | 2014-02-05 | 2016-10-11 | Gilead Sciences, Inc. | Methods of treating patients co-infected with HIV and tuberculosis |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| CA2980362C (en) | 2015-04-02 | 2020-02-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| US6544540B2 (en) * | 1998-07-29 | 2003-04-08 | Syngenta Limited | Base-triggered release microcapsules |
| BRPI0306214B1 (pt) * | 2002-11-20 | 2017-08-08 | Japan Tobacco Inc. | 4-oxoquinoline compound and use of this as a hiv integrase inhibitor |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| EP3287130A1 (en) * | 2004-05-21 | 2018-02-28 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and protease inhibitors |
| US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| KR101524165B1 (ko) * | 2005-12-30 | 2015-06-01 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법 |
| SI2049506T2 (sl) * | 2006-07-07 | 2024-07-31 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtikov |
| HRP20090213B1 (hr) * | 2006-09-12 | 2016-12-02 | Gilead Sciences, Inc. | Postupak i međuprodukti u pripravi inhibitora integraze |
| CN103356622A (zh) * | 2007-06-29 | 2013-10-23 | 吉里德科学公司 | 治疗用组合物及其用途 |
| CN101686972B (zh) * | 2007-06-29 | 2013-08-14 | 吉里德科学公司 | 治疗用组合物和方法 |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX342377B (es) * | 2008-05-02 | 2016-09-27 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| US20110000941A1 (en) * | 2009-07-06 | 2011-01-06 | Volk J Patrick | Apparatus and System for Carrying a Digital Media Player |
-
2008
- 2008-06-26 CN CN2008800228167A patent/CN101686972B/zh not_active Expired - Fee Related
- 2008-06-26 US US12/147,041 patent/US20090093467A1/en not_active Abandoned
- 2008-06-26 US US12/666,991 patent/US20100331331A1/en not_active Abandoned
- 2008-06-26 AR ARP080102759A patent/AR067183A1/es not_active Application Discontinuation
- 2008-06-26 NZ NZ582086A patent/NZ582086A/en not_active IP Right Cessation
- 2008-06-26 TW TW097123983A patent/TW200914011A/zh unknown
- 2008-06-26 EA EA200971093A patent/EA200971093A1/ru unknown
- 2008-06-26 EP EP08772024A patent/EP2167088A1/en not_active Withdrawn
- 2008-06-26 AP AP2009005074A patent/AP2965A/xx active
- 2008-06-26 CN CN201310302662.XA patent/CN103480000A/zh active Pending
- 2008-06-26 MX MX2009013829A patent/MX2009013829A/es unknown
- 2008-06-26 WO PCT/US2008/068339 patent/WO2009006199A1/en not_active Ceased
- 2008-06-26 KR KR1020107001981A patent/KR20100040892A/ko not_active Ceased
- 2008-06-26 AU AU2008270630A patent/AU2008270630B2/en not_active Ceased
- 2008-06-26 JP JP2010515112A patent/JP5547066B2/ja not_active Expired - Fee Related
- 2008-06-26 CA CA002692101A patent/CA2692101A1/en not_active Abandoned
- 2008-06-26 BR BRPI0813000-0A2A patent/BRPI0813000A2/pt not_active IP Right Cessation
- 2008-06-26 SG SG2012046934A patent/SG182229A1/en unknown
-
2009
- 2009-12-15 IL IL202744A patent/IL202744A0/en unknown
- 2009-12-21 CO CO09146055A patent/CO6251237A2/es not_active Application Discontinuation
-
2010
- 2010-01-22 EC EC2010009897A patent/ECSP109897A/es unknown
-
2013
- 2013-07-08 JP JP2013142322A patent/JP5769763B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/281,798 patent/US20140343063A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094707A patent/JP2015143278A/ja not_active Withdrawn
-
2016
- 2016-10-19 US US15/298,084 patent/US20170136001A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090093467A1 (en) | 2009-04-09 |
| US20100331331A1 (en) | 2010-12-30 |
| AP2965A (en) | 2014-09-30 |
| BRPI0813000A2 (pt) | 2014-12-23 |
| CN101686972B (zh) | 2013-08-14 |
| CA2692101A1 (en) | 2009-01-08 |
| IL202744A0 (en) | 2010-06-30 |
| AR067183A1 (es) | 2009-09-30 |
| CN103480000A (zh) | 2014-01-01 |
| SG182229A1 (en) | 2012-07-30 |
| JP2015143278A (ja) | 2015-08-06 |
| NZ582086A (en) | 2012-07-27 |
| CN101686972A (zh) | 2010-03-31 |
| WO2009006199A1 (en) | 2009-01-08 |
| JP2010532372A (ja) | 2010-10-07 |
| MX2009013829A (es) | 2010-03-10 |
| JP2013199495A (ja) | 2013-10-03 |
| US20170136001A1 (en) | 2017-05-18 |
| EP2167088A1 (en) | 2010-03-31 |
| US20140343063A1 (en) | 2014-11-20 |
| AU2008270630A1 (en) | 2009-01-08 |
| ECSP109897A (es) | 2010-03-31 |
| KR20100040892A (ko) | 2010-04-21 |
| AU2008270630B2 (en) | 2014-01-16 |
| AP2009005074A0 (en) | 2009-12-31 |
| JP5547066B2 (ja) | 2014-07-09 |
| TW200914011A (en) | 2009-04-01 |
| CO6251237A2 (es) | 2011-02-21 |
| JP5769763B2 (ja) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200971093A1 (ru) | Терапевтические композиции и их применение | |
| EA200971096A1 (ru) | Терапевтические композиции и их применение | |
| EA201291301A1 (ru) | Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич | |
| BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
| EA201391395A1 (ru) | Терапевтические соединения | |
| EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
| WO2014134566A3 (en) | Amide compounds for the treatment of hiv | |
| EA201270247A1 (ru) | Способы применения с-мет-модуляторов | |
| EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| EA200901241A1 (ru) | Соединения для лечения гепатита с | |
| PH12013500011A1 (en) | Napht-2-ylacetic acid derivatives to treat aids | |
| BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
| EA201290053A1 (ru) | Ингибиторы вирусов flaviviridae | |
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| EA201290632A1 (ru) | Производные бетулина | |
| AU2011286276A8 (en) | Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases | |
| EA201170441A1 (ru) | Терапевтические противовирусные пептиды | |
| UA110983C2 (uk) | Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету | |
| EA201190293A1 (ru) | Пролекарства триптолида | |
| EA201000895A1 (ru) | Композиции и способы для лечения лизосомных болезней | |
| EA201270275A1 (ru) | Кристаллическое соединение пиридазина | |
| EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств | |
| EA201001566A1 (ru) | Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний |